FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
07/03/2023
Back to search
Official data from USPTO
L-PAMPO
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
28
Latest update
07/03/2023
Trademark type
Combined
Nice classes
5
Filing date
06/23/2021
Registration date
03/07/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/07/2023
Last transaction
03/07/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
99
Owner location
KR
Examiner
QUILICI, BRENDAN
Law office
N50
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the wording "L-PAMPO" in black stylized font.
Holders and representatives
Holders
CHA Vaccine Research Institute Co., Ltd
Representatives
Cynthia A. Moyer Fredrikson & Byron, P.A.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Vaccines for cattle; oral vaccine preparations; veterinary vaccines; viral vaccines; vaccines; adjuvants for use with vaccines; vaccine preparations; Veterinary substances and preparations for treating and preventing viruses and other infectious diseasesinflammatory diseasesgenetic diseasesneurological diseasesautoimmune diseasescancer; human vaccine preparations; anti-microbial preparations for treating and preventing viruses and other infectious diseases; pharmaceutical preparations for treating and preventing viruses and other infectious diseasesinflammatory diseasesgenetic diseasesneurological diseasesautoimmune diseasescancer; pharmaceutical compositions for the treatment and prevention of viruses and other infectious diseasesinflammatory diseasesgenetic diseasesneurological diseasesautoimmune diseasescancer; reagents for medical use; diagnostic reagents for medical use for immunization diseases; diagnostic reagents for medical or veterinary purposes; clinical diagnostic reagents for medical use; preparations of microorganisms for medical or veterinary use; hepatitis vaccine; preparations for treatment of hepatitis; vaccines against flu; immunostimulants; immunomodulators; pharmaceutical preparations for the prevention of disorders of the immune system; pharmaceutical preparations for the prevention of diseases of the immune system; pharmaceutical preparations for regulating the immune system; pharmaceutical products for the treatment of viral diseases; veterinary vaccines for bovine animals; veterinary vaccines for sheep; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical products for the treatment of viral and infectious diseasesfor the treatment of cancer; pharmaceutical products for the treatment of cancer; drug delivery agents in the form of aqueous particles that provide a controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of injectableinhalableintranasaloralsublingualtransdermaltopical compositions that facilitate the delivery of pharmaceutical preparations; pharmaceutical preparations for the treatment of autoimmune disorders; pharmaceutical preparations for the prevention of autoimmune disorders; pharmaceutical preparations for the prevention of autoimmune diseases; pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders; anti-infectives; anti-viral agents; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of tumours; biopharmaceuticals for the treatment of cancer; biological preparations for the treatment of cancer; compounds for treating cancer; pharmaceutical preparations and substances for the prevention of cancer
Publications
History of USPTO decisions and trademark events.
28 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
06/09/2023
FIMP
FINAL DISPOSITION PROCESSED
06/09/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/07/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/07/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
03/07/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
02/06/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/18/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
01/18/2023
GPNX
NOTIFICATION PROCESSED BY IB
12/21/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/20/2022
PUBO
PUBLISHED FOR OPPOSITION
12/20/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/30/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
11/30/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/30/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/16/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/27/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/26/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/26/2022
RFNT
REFUSAL PROCESSED BY IB
05/24/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/02/2022
RFRR
REFUSAL PROCESSED BY MPU
05/02/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/21/2022
CNRT
NON-FINAL ACTION WRITTEN
03/20/2022
DOCK
ASSIGNED TO EXAMINER
03/15/2022
MAFR
APPLICATION FILING RECEIPT MAILED
08/17/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/13/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/12/2021
Continuous trademark protection
Get notified about every new filing that threatens L-PAMPO or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.